PE20060947A1 - Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion - Google Patents

Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion

Info

Publication number
PE20060947A1
PE20060947A1 PE2005001297A PE2005001297A PE20060947A1 PE 20060947 A1 PE20060947 A1 PE 20060947A1 PE 2005001297 A PE2005001297 A PE 2005001297A PE 2005001297 A PE2005001297 A PE 2005001297A PE 20060947 A1 PE20060947 A1 PE 20060947A1
Authority
PE
Peru
Prior art keywords
staurosporin
benzoyl
procedure
preparation
crystalline form
Prior art date
Application number
PE2005001297A
Other languages
English (en)
Inventor
Pascale Hoehn
Bernd Koch
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35501294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060947(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20060947A1 publication Critical patent/PE20060947A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMA CRISTALINA II DE N-BENZOIL-ESTAUROSPORINA QUE ES (9a,10b,11b,13a)-N-(2,3,10,11,12,13-HEXAHIDRO-10-METOXI-9-METIL-1-OXO-9,13-EPOXI-1h,9H-DI-INDOLO-[1,2,3,gh:3',2',1'm]-PIRROLO[3,4-j][1,7]-BENZODIAZONIN-11-IL)-N-METIL-BENZAMIDA) CARACTERIZADO POR PRESENTAR DIFRACCION DE RAYOS X, EXPRESADO EN TERMINOS DE ANGULOS 2 TETA, QUE INCLUYE 5 O MAS PICOS SELECCIONADOS ENTRE 3.4, 6.0, 7.8, 8.7, 9.2, 9.7, 10.1, 10.4, 11.2, 12.6, 14.1, 15.7, 16.8, 18.2, 18.9, 19.3, 19.6, 20.2 Y 24.5 ± 0.2 GRADOS. DICHA FORMA CRISTALINA PRESENTA UN ESPECTRO DE ABSORCION INFRARROJO COMPRENDIDO ENTRE 789 A 3055 cm-1 ± 2 cm-1. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y PURIFICACION. DICHO COMPUESTO ES UTIL EN EL TRATAMIENTO DE TUMORES COMO CANCER DE MAMA, CANCER DE COLON, CANCER DE OVARIO
PE2005001297A 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion PE20060947A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62534304P 2004-11-05 2004-11-05
US64213105P 2005-01-07 2005-01-07

Publications (1)

Publication Number Publication Date
PE20060947A1 true PE20060947A1 (es) 2006-10-30

Family

ID=35501294

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2009000199A PE20090433A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion
PE2012002519A PE20130377A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion
PE2005001297A PE20060947A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2009000199A PE20090433A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion
PE2012002519A PE20130377A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion

Country Status (31)

Country Link
US (2) US8198435B2 (es)
EP (3) EP2955186A1 (es)
JP (4) JP5057986B2 (es)
KR (3) KR101333851B1 (es)
CN (2) CN102993213A (es)
AR (1) AR052322A1 (es)
AU (2) AU2005300693B2 (es)
BR (1) BRPI0517689A (es)
CA (1) CA2584911C (es)
CY (1) CY1113059T1 (es)
DK (1) DK1812448T3 (es)
EC (1) ECSP12007431A (es)
ES (1) ES2388142T3 (es)
GT (1) GT200500311A (es)
HK (2) HK1211587A1 (es)
HR (1) HRP20120652T1 (es)
IL (3) IL182691A (es)
JO (1) JO2897B1 (es)
MA (1) MA29033B1 (es)
MX (2) MX346525B (es)
MY (2) MY154878A (es)
NO (2) NO338960B1 (es)
NZ (3) NZ599033A (es)
PE (3) PE20090433A1 (es)
PL (1) PL1812448T3 (es)
PT (1) PT1812448E (es)
RU (2) RU2394038C2 (es)
SI (1) SI1812448T1 (es)
TN (1) TNSN07165A1 (es)
TW (4) TWI433852B (es)
WO (1) WO2006048296A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101462693B1 (ko) * 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
KR20160008267A (ko) 2014-07-14 2016-01-22 주식회사 윈스 네트워크 기반 영상감시체계에서의 사용자 행위 분석 시스템
EP3592749A1 (en) * 2017-03-06 2020-01-15 Teva Pharmaceutical Works Ltd. Solid state forms of midostaurin
WO2019215759A1 (en) * 2018-05-09 2019-11-14 Alaparthi Lakshmi Prasad An improved process for preparation of midostaurin
IT201900004729A1 (it) 2019-03-29 2020-09-29 Procos Spa Processo per la preparazione di midostaurina ad elevato grado di purezza
US20220242880A1 (en) * 2019-06-24 2022-08-04 Dr. Reddy?s Laboratories Limited Process for preparation of midostaurin
IT201900014346A1 (it) 2019-08-08 2021-02-08 Procos Spa Processo per la preparazione di midostaurina amorfa con un basso contenuto di solvente organico residuo
IT202000004291A1 (it) 2020-03-02 2021-09-02 Indena Spa Processo per la purificazione di alcaloidi indolo carbazolici
CN111393454A (zh) * 2020-05-07 2020-07-10 奥锐特药业(天津)有限公司 米哚妥林的新晶型及其制备方法
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
WO2023205504A1 (en) * 2022-04-22 2023-10-26 Rutgers, The State University Of New Jersey Formulations and methods for treating epidermolysis bullosa simplex and related conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
JPS60185719A (ja) 1984-03-06 1985-09-21 Ajinomoto Co Inc 抗腫瘍剤
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5073633A (en) * 1989-03-23 1991-12-17 Bristol-Myers Company BMY-41950 antitumor antibiotic
US5096330A (en) * 1990-06-21 1992-03-17 M-B-W Inc. Pitch control mechanism for a surface finishing machine
JPH05247055A (ja) * 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
JPH05247955A (ja) 1992-03-06 1993-09-24 Taisei Corp 擁壁の施工方法
ES2136103T3 (es) 1992-06-22 1999-11-16 Kyowa Hakko Kogyo Kk Procedimiento para la preparacion de derivados de estaurosporina.
WO1995032975A1 (en) * 1994-06-01 1995-12-07 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
RU2191175C2 (ru) 1995-12-11 2002-10-20 Сефалон, Инкорпорейтед Конденсированные изоиндолоны в качестве ингибиторов протеинкиназы с
US6878804B1 (en) 1999-08-30 2005-04-12 University Of Zurich Synthesis of template-fixed β-hairpin loop mimetics
PT1372611E (pt) 2001-03-26 2006-08-31 Novartis Ag Composicao farmaceutica compreendendo uma estaurosporina francamente soluvel em agua, um tensioactivo et um polimero soluvel em agua
KR100407758B1 (ko) 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
US7608420B2 (en) * 2003-04-22 2009-10-27 Lonza Ag Process for the recovery of staurosporine from a fermentation broth

Also Published As

Publication number Publication date
MX2007005429A (es) 2007-05-18
JO2897B1 (en) 2015-09-15
JP2012149099A (ja) 2012-08-09
EP2272850A3 (en) 2011-09-21
TW200628474A (en) 2006-08-16
CA2584911C (en) 2017-10-24
TNSN07165A1 (en) 2008-11-21
CY1113059T1 (el) 2016-04-13
TW201247680A (en) 2012-12-01
EP2272850B1 (en) 2017-05-10
KR101289998B1 (ko) 2013-07-30
PE20130377A1 (es) 2013-04-03
RU2394038C2 (ru) 2010-07-10
JP5701246B2 (ja) 2015-04-15
KR20070083979A (ko) 2007-08-24
NO338960B1 (no) 2016-11-07
EP1812448B1 (en) 2012-05-23
KR101265850B1 (ko) 2013-05-20
US8198435B2 (en) 2012-06-12
JP2015063569A (ja) 2015-04-09
IL182691A0 (en) 2007-09-20
PE20090433A1 (es) 2009-05-05
TWI530500B (zh) 2016-04-21
TW201247681A (en) 2012-12-01
WO2006048296A1 (en) 2006-05-11
NZ554653A (en) 2010-10-29
NZ588025A (en) 2012-04-27
TWI433852B (zh) 2014-04-11
HK1211587A1 (en) 2016-05-27
JP2008518995A (ja) 2008-06-05
HK1108881A1 (en) 2008-05-23
TW201446773A (zh) 2014-12-16
IL182691A (en) 2013-02-28
RU2009137788A (ru) 2011-04-20
ECSP12007431A (es) 2012-06-29
DK1812448T3 (da) 2012-08-27
JP5057986B2 (ja) 2012-10-24
AR052322A1 (es) 2007-03-14
NO20161152A1 (no) 2007-05-30
AU2005300693B2 (en) 2010-08-19
TWI455941B (zh) 2014-10-11
PL1812448T3 (pl) 2012-10-31
MX346525B (es) 2017-03-23
CN102627658A (zh) 2012-08-08
NO20072290L (no) 2007-05-30
MY154878A (en) 2015-08-14
NO340404B1 (no) 2017-04-18
AU2009245817A1 (en) 2009-12-24
EP2955186A1 (en) 2015-12-16
US8710216B2 (en) 2014-04-29
MY147404A (en) 2012-11-30
AU2005300693A1 (en) 2006-05-11
NZ599033A (en) 2012-09-28
RU2007120695A (ru) 2008-12-10
CA2584911A1 (en) 2006-05-11
PT1812448E (pt) 2012-08-24
TWI530501B (zh) 2016-04-21
IL217571A (en) 2017-07-31
BRPI0517689A (pt) 2008-10-14
IL207702A0 (en) 2010-12-30
US20090137552A1 (en) 2009-05-28
MA29033B1 (fr) 2007-11-01
EP2272850A2 (en) 2011-01-12
CN102993213A (zh) 2013-03-27
RU2467012C2 (ru) 2012-11-20
KR20120101600A (ko) 2012-09-13
KR101333851B1 (ko) 2013-11-27
IL207702A (en) 2016-09-29
EP1812448A1 (en) 2007-08-01
SI1812448T1 (sl) 2012-09-28
AU2009245817B2 (en) 2013-02-21
JP2017061578A (ja) 2017-03-30
US20120322789A1 (en) 2012-12-20
ES2388142T3 (es) 2012-10-09
GT200500311A (es) 2006-05-22
KR20120101601A (ko) 2012-09-13
HRP20120652T1 (hr) 2012-09-30

Similar Documents

Publication Publication Date Title
PE20060947A1 (es) Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion
MY156814A (en) Organic compounds and their uses
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
TW200800963A (en) Chemical compounds
PT1853588E (pt) Compostos químicos
EP2400847A4 (en) SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
WO2007127263A3 (en) Therapeutic uses of urolithins
HRP20130458T1 (hr) Malatna sol od n-(4-{[6,7-bis(metiloksi)kinolin-4-il]oksi} fenil-n'-(4-fluorofenil)ciklopropan-1,1-dikarboksamida i njezini kristalni oblici za lijeäśenje raka
MX2009005935A (es) Compuestos biciclicos y su uso como anti-diabeticos.
NZ577916A (en) Cyclopamine analogs
WO2006091693A3 (en) Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor
CL2007003502A1 (es) Compuestos derivados de pirimidin-amina, moduladores de jnk; proceso de preparacion; composiciones farmaceuticas; y uso para el tratamiento de artritis reumatoide, asma, diabetes tipo ii, enfermedad de alzheimer, enfermedad de parkinson y apoplejia.
HN2009000784A (es) Dihidropirazolonas sustituidas
TW200728302A (en) Chemical compounds VI
CA2776342C (en) Agomelatine and pharmaceutical compositions thereof
TW200730493A (en) Chemical compounds
EP1727530A4 (en) TOPICAL FORMULATIONS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS
TW200602036A (en) Diphenylazetidone derivates
WO2009030224A3 (de) Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen
GEP20125404B (en) Tricyclic compounds and their use as glucocorticoid receptor modulators
DOP2006000062A (es) Derivados de acido pirimidincarboxilico y su uso
PE20030923A1 (es) Forma polimorfica cristalina de clorhidrato de irinotecan
SI2024368T1 (sl) Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine
EP1863520A4 (en) USE OF INTERLEUKIN 17E FOR THE TREATMENT OF CANCER

Legal Events

Date Code Title Description
FC Refusal